Filing Flows › Alignment Healthcare (ALHC) › Stock forecast & fair value
Alignment Healthcare (ALHC) stock forecast and fair value
Alignment Healthcare (ALHC) trades at $7.27. 12 analysts' median price target is $10.00 (+38%), from $8.00 to $17.00. Across 11 valuation methods the middle fair value is $2.57 (-65%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| P/E vs peers | $2.22 | $3.14 | $4.51 | -57% |
| P/E vs peers, weighted | $1.88 | $2.57 | $3.45 | -65% |
| Residual income | $1.37 | $1.42 | $1.47 | -80% |
| P/B vs ROE (insurer peers) | $0.59 | $2.42 | $4.26 | -67% |
| Analysts' price targets | $8.00 | $10.79 | $17.00 | +48% |
| Justified P/B (Gordon growth) | $1.79 | $2.24 | $3.01 | -69% |
| Stage-weighted value (financial (bank / insurer)) | $1.30 | $2.13 | $3.08 | -71% |
| Combined forecast (3 months) | $5.93 | $7.54 | $9.35 | +4% |
| Graham number | $1.63 | $2.00 | $2.31 | -72% |
| Graham formula (revised) | $3.22 | $3.81 | $4.41 | -48% |
Alignment Healthcare's latest quarter
Alignment Healthcare, Q3 2026: revenue $1.4B (+37% year over year), operating margin -0.3%, net loss $8.1M, operating cash flow $47.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ALHC stock?
The median of 12 analysts' 12-month targets is $10.00, +38% from $7.27; the range is $8.00 to $17.00. The average rating is buy.
What is Alignment Healthcare's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $1.42 and $10.79, with a middle value of $2.57 against a price of $7.27. Each method's assumptions are on the page.
Does Alignment Healthcare usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is ALHC stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.